Clinical Results
FDA Approval
The FDA approval of Xtoro was based on two randomized multicenter, vehicle controlled clinical trials. Xtoro dosed four drops twice daily for 7 days was superior to its vehicle for both clinical and microbiological outcomes, as well as in time to cessation of ear pain in patients with acute otitis externa. Among 560 patients (161 with an otowick) that were pathogen positive (baseline microbiological specimen that contained Staphylococcus aureus and/or Pseudomonas aeruginosa), clinical cure on Day 11 was 71% in Xtoro versus 37% in Vehicle. Among 1,234 patients who received study treatment (Intent to Treat population (ITT)), aged 6 months to 85 years, clinical cures were 71% for Xtoro and 50% in Vehicle.